Literature DB >> 29505961

Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span.

Neema S Patel1, Jennifer Klett1, Katy Pilarzyk1, Dong Ik Lee2, David Kass2, Frank S Menniti3, Michy P Kelly4.   

Abstract

3',5'-Cyclic nucleotide phosphodiesterases (PDEs) degrade 3',5' cyclic adenonosine monophosphate (cAMP) and 3',5' cyclic guanosine monophosphate (cGMP), with PDE9A having the highest affinity for cGMP. We show PDE9A6 and 3 novel PDE9 isoforms (PDE9X-100, PDE9X-120, and PDE9X-175) are reliably detected in the brain and lung of mice, whereas PDE9A2 and other isoforms are found elsewhere. PDE9A localizes to the membrane in all organs except the bladder, where it is cytosolic. Brain additionally shows PDE9 in the nuclear fraction. PDE9A mRNA expression/localization dramatically changes across neurodevelopment in a manner that is strikingly consistent between mice and humans (i.e., decreased expression in the hippocampus and cortex and inverted-U in the cerebellum). Study of the 4 PDE9 isoforms in the mouse brain from postnatal day 7 through 24 months similarly identifies dramatic effects of age on expression and subcellular compartmentalization that are isoform specific and brain region specific. Finally, PDE9A mRNA is elevated in the aged human hippocampus with dementia when there is a history of traumatic brain injury. Thus, brain PDE9 is localized to preferentially regulate nuclear- and membrane-proximal pools of cGMP, and its function likely changes across the life span.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging; Allen institute for Brain Science; Cerebellum; Development; GAPDH; Hippocampus; Phosphodiesterase; Ponceau; Prefrontal cortex; Striatum; cGMP

Mesh:

Substances:

Year:  2018        PMID: 29505961      PMCID: PMC5871571          DOI: 10.1016/j.neurobiolaging.2018.01.019

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  49 in total

1.  The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task.

Authors:  Joshua D Vardigan; Antonella Converso; Pete H Hutson; Jason M Uslaner
Journal:  J Neurogenet       Date:  2011-11-09       Impact factor: 1.250

2.  mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain.

Authors:  Wilma C G Van Staveren; Harry W M Steinbusch; Marjanne Markerink-Van Ittersum; David R Repaske; Michael F Goy; Jun Kotera; Kenji Omori; Joseph A Beavo; Jan De Vente
Journal:  J Comp Neurol       Date:  2003-12-22       Impact factor: 3.215

3.  Application of neurophysiological biomarkers for Huntington's disease: evaluating a phosphodiesterase 9A inhibitor.

Authors:  Dávid Nagy; Francis D Tingley; Milan Stoiljkovic; Mihály Hajós
Journal:  Exp Neurol       Date:  2014-10-12       Impact factor: 5.330

4.  The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.

Authors:  P H Hutson; E N Finger; B C Magliaro; S M Smith; A Converso; P E Sanderson; D Mullins; L A Hyde; B K Eschle; Z Turnbull; H Sloan; M Guzzi; X Zhang; A Wang; D Rindgen; R Mazzola; J A Vivian; D Eddins; J M Uslaner; R Bednar; C Gambone; W Le-Mair; M J Marino; N Sachs; G Xu; S Parmentier-Batteur
Journal:  Neuropharmacology       Date:  2011-05-19       Impact factor: 5.250

5.  Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP.

Authors:  Katja S Kroker; Georg Rast; Riccardo Giovannini; Anelise Marti; Cornelia Dorner-Ciossek; Holger Rosenbrock
Journal:  Neuropharmacology       Date:  2012-01-04       Impact factor: 5.250

6.  Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues.

Authors:  Viktor Lakics; Eric H Karran; Frank G Boess
Journal:  Neuropharmacology       Date:  2010-05-21       Impact factor: 5.250

7.  Beta-amyloid peptides decrease soluble guanylyl cyclase expression in astroglial cells.

Authors:  María Antonia Baltrons; Carlos E Pedraza; Michael T Heneka; Agustina García
Journal:  Neurobiol Dis       Date:  2002-07       Impact factor: 5.996

8.  PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition.

Authors:  Katja S Kroker; Chantal Mathis; Anelise Marti; Jean-Christophe Cassel; Holger Rosenbrock; Cornelia Dorner-Ciossek
Journal:  Neurobiol Aging       Date:  2014-03-26       Impact factor: 4.673

Review 9.  Influence of parallel fiber-Purkinje cell synapse formation on postnatal development of climbing fiber-Purkinje cell synapses in the cerebellum.

Authors:  K Hashimoto; T Yoshida; K Sakimura; M Mishina; M Watanabe; M Kano
Journal:  Neuroscience       Date:  2008-12-31       Impact factor: 3.590

10.  Novel, primate-specific PDE10A isoform highlights gene expression complexity in human striatum with implications on the molecular pathology of bipolar disorder.

Authors:  C M MacMullen; K Vick; R Pacifico; M Fallahi-Sichani; R L Davis
Journal:  Transl Psychiatry       Date:  2016-02-23       Impact factor: 6.222

View more
  11 in total

1.  Cyclic nucleotide signalling compartmentation by PDEs in cultured vascular smooth muscle cells.

Authors:  Liang Zhang; Kaouter Bouadjel; Boris Manoury; Grégoire Vandecasteele; Rodolphe Fischmeister; Véronique Leblais
Journal:  Br J Pharmacol       Date:  2019-04-24       Impact factor: 8.739

2.  Conserved age-related increases in hippocampal PDE11A4 cause unexpected proteinopathies and cognitive decline of social associative memories.

Authors:  Katy Pilarzyk; Latarsha Porcher; William R Capell; Steven D Burbano; Jeff Davis; Janet L Fisher; Nicole Gorny; Siena Petrolle; Michy P Kelly
Journal:  Aging Cell       Date:  2022-09-08       Impact factor: 11.005

Review 3.  Pharmacological modulation of phosphodiesterase-7 as a novel strategy for neurodegenerative disorders.

Authors:  Heena Khan; Chanchal Tiwari; Amarjot Kaur Grewal; Thakur Gurjeet Singh; Simran Chauhan; Gaber El-Saber Batiha
Journal:  Inflammopharmacology       Date:  2022-10-22       Impact factor: 5.093

4.  Phosphodiesterases PDE2A and PDE10A both change mRNA expression in the human brain with age, but only PDE2A changes in a region-specific manner with psychiatric disease.

Authors:  Reagan Farmer; Steven D Burbano; Neema S Patel; Angelo Sarmiento; Abigail J Smith; Michy P Kelly
Journal:  Cell Signal       Date:  2020-02-29       Impact factor: 4.315

Review 5.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

Review 6.  A Perspective on Natural and Nature-Inspired Small Molecules Targeting Phosphodiesterase 9 (PDE9): Chances and Challenges against Neurodegeneration.

Authors:  Giovanni Ribaudo; Maurizio Memo; Alessandra Gianoncelli
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-13

7.  The Role of PDE11A4 in Social Isolation-Induced Changes in Intracellular Signaling and Neuroinflammation.

Authors:  Katy Pilarzyk; Reagan Farmer; Latarsha Porcher; Michy P Kelly
Journal:  Front Pharmacol       Date:  2021-11-23       Impact factor: 5.810

8.  A genetic basis for friendship? Homophily for membrane-associated PDE11A-cAMP-CREB signaling in CA1 of hippocampus dictates mutual social preference in male and female mice.

Authors:  Abigail J Smith; Reagan Farmer; Katy Pilarzyk; Latarsha Porcher; Michy P Kelly
Journal:  Mol Psychiatry       Date:  2021-07-28       Impact factor: 13.437

9.  Real-Time Imaging Reveals Augmentation of Glutamate-Induced Ca2+ Transients by the NO-cGMP Pathway in Cerebellar Granule Neurons.

Authors:  Michael Paolillo; Stefanie Peters; Andrea Schramm; Jens Schlossmann; Robert Feil
Journal:  Int J Mol Sci       Date:  2018-07-26       Impact factor: 5.923

10.  Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-Oxide.

Authors:  John F Harms; Frank S Menniti; Christopher J Schmidt
Journal:  Front Neurosci       Date:  2019-08-23       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.